Experts Say COVID-19 Battle Needs More Funding, Cooperation
Coronavirus Causes BIO-Europe Spring Conference To Go ‘Virtual’
Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.
Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.